MedTrace Logo

A Study to Investigate Dosage, Effectiveness, and Safety of Perampanel When Used as First Add-on Therapy in Participants >=12 Years With Partial Onset Seizures With or Without Secondary Generalization or With Primary Generalized Tonic-Clonic Seizures Associated With Idiopathic Generalized Epilepsy

NCT04252846 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 191

Last updated 2023-02-09

No results posted yet for this study

Summary

The primary purpose of this study is to assess the retention rate of perampanel as a reliable proxy for overall effectiveness and tolerability in participants aged at least 12 years who are prescribed perampanel (for partial onset seizures \[POS\] with or without secondary generalization \[SG\] or for primary generalized tonic-clonic seizures \[PGTCS\] associated with idiopathic generalized epilepsy \[IGE\] as first adjunctive to antiepileptic drug (AED) monotherapy as part of their routine clinical care.

Conditions

  • Idiopathic Generalized Epilepsy
  • Partial Onset Seizures
  • Generalised Tonic-Clonic Seizures

Interventions

DRUG

Perampanel

Perampanel oral tablets or oral suspension.

Sponsors & Collaborators

  • Eisai Limited

    lead INDUSTRY

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-07-20
Primary Completion
2023-01-12
Completion
2023-01-12
FDA Drug
Yes

Countries

  • Denmark
  • France
  • Germany
  • Italy
  • Portugal
  • Russia
  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04252846 on ClinicalTrials.gov